Editas Medicine, Inc. is a pioneering clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing transformative genomic therapies using its proprietary CRISPR technology. The company is at the forefront of addressing serious genetic disorders, with a robust pipeline of innovative therapeutic candidates designed to enhance patient outcomes and redefine the treatment landscape for inherited conditions. Editas presents a compelling investment opportunity for institutional investors keen on supporting cutting-edge advancements in genetic medicine and contributing to the future of healthcare innovation. Show more

Location: 11 HURLEY STREET, CAMBRIDGE, MA, UNITED STATES, 02141, Cambridge, MA, 02141, USA | Website: https://www.editasmedicine.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

162.5M

52 Wk Range

$0.91 - $4.54

Previous Close

$1.66

Open

$1.78

Volume

1,930,416

Day Range

$1.73 - $1.84

Enterprise Value

44.85M

Cash

165.6M

Avg Qtr Burn

-30.84M

Insider Ownership

0.27%

Institutional Own.

48.91%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EDIT-401 Details Hyperlipidemia, Atherosclerotic cardiovascular disease (ASCVD)	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Reni-cel (renizgamglogene autogedtemcel) (EDIT-301) Details Genetic disorder, Beta thalessemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EDIT-101 Details Rare diseases, Eye disease , Rare genetic disease, Hepatitis C	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Reni-cel (renizgamglogene autogedtemcel) (EDIT-301) Details Sickle cell disease, Genetic disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.